PRCT (PROCEPT BioRobotics Corporation Common Stock) Stock Analysis - Politician Trades

PROCEPT BioRobotics Corporation Common Stock (PRCT) is a publicly traded Healthcare sector company. As of May 21, 2026, PRCT trades at $28.15 with a market cap of $1.48B and a P/E ratio of -16.03. PRCT moved +8.57% today. Year to date, PRCT is -15.13%; over the trailing twelve months it is -52.50%. Its 52-week range spans $19.35 to $103.81. Analyst consensus is buy with an average price target of $36.50. Rallies surfaces PRCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded PRCT stock?

Rallies tracks politician and congressional stock disclosures for PRCT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

PRCT Key Metrics

Key financial metrics for PRCT
MetricValue
Price$28.15
Market Cap$1.48B
P/E Ratio-16.03
EPS$-1.72
Dividend Yield0.00%
52-Week High$103.81
52-Week Low$19.35
Volume58
Avg Volume0
Revenue (TTM)$308.05M
Net Income$-95.57M
Gross Margin63.70%

Latest PRCT News

Recent PRCT Insider Trades

  • Nouri Alaleh sold 3.03K (~$78.26K) on Mar 19, 2026.
  • Nouri Alaleh sold 2.33K (~$60.97K) on Mar 19, 2026.
  • Nouri Alaleh sold 304 (~$8.56K) on Mar 17, 2026.

PRCT Analyst Consensus

11 analysts cover PRCT: 0 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $36.50.

Common questions about PRCT

Which politicians traded PRCT stock?
Rallies tracks politician and congressional stock disclosures for PRCT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in PRCT?
Yes. Rallies tracks politician and congressional stock disclosures for PRCT, including reported purchases, sales, dates, owners, and trade amounts when available.
Is PRCT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PRCT. It does not provide personalized investment advice.
PRCT

PRCT